Product References
Elucidating the role of excision repair cross-complement group 1 in oral epithelial dysplasia and early invasive squamous cell carcinoma: An immunohistochemical study.
Journal of oral and maxillofacial pathology : JOMFP
Kulkarni S,Solomon M,Pankaj D,Carnelio S,Chandrashekar C,Shetty N
Published figure using ERCC1 monoclonal antibody (Product # MA5-13912) in Immunohistochemistry
Thu Apr 14 00:00:00 EDT 2022
Elucidating the role of excision repair cross-complement group 1 in oral epithelial dysplasia and early invasive squamous cell carcinoma: An immunohistochemical study.
Journal of oral and maxillofacial pathology : JOMFP
Kulkarni S,Solomon M,Pankaj D,Carnelio S,Chandrashekar C,Shetty N
Published figure using ERCC1 monoclonal antibody (Product # MA5-13912) in Immunohistochemistry
Thu Apr 14 00:00:00 EDT 2022
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
American journal of clinical oncology
Cubillo A,Rodriguez-Pascual J,López-Ríos F,Plaza C,García E,Álvarez R,de Vicente E,Quijano Y,Hernando O,Rubio C,Perea S,Sanchez G,Hidalgo M
MA5-13912 was used in immunohistochemistry to perform a phase II clinical trial in patients with advanced metastatic colorectal cancer to study the feasibility of a targeted personalized chemotherapy approach
Wed Jun 01 00:00:00 EDT 2016
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
BMC cancer
Koussounadis A,Langdon SP,Um I,Kay C,Francis KE,Harrison DJ,Smith VA
MA5-13912 was used in immunohistochemistry - paraffin section to utilize ovarian cancer xenograft models to study dynamic modulation of phosphoprotein expression
Thu Mar 10 00:00:00 EST 2016
Factors affecting platinum sensitivity in cervical cancer.
Oncology letters
Kato R,Hasegawa K,Torii Y,Udagawa Y,Fukasawa I
MA5-13912 was used in immunohistochemistry - paraffin section to assess the association between nedaplatin sensitivity and the expression of biological factors relevant to cervical cancer
Tue Dec 01 00:00:00 EST 2015
UHRF1 contributes to DNA damage repair as a lesion recognition factor and nuclease scaffold.
Cell reports
Tian Y,Paramasivam M,Ghosal G,Chen D,Shen X,Huang Y,Akhter S,Legerski R,Chen J,Seidman MM,Qin J,Li L
MA5-13912 was used in western blot to study the role of UHRF1 to DNA lesions.
Tue Mar 31 00:00:00 EDT 2015
Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
International journal of oncology
Steffensen KD,Smoter M,Waldstrøm M,Grala B,Bodnar L,Stec R,Szczylik C,Jakobsen A
MA5-13912 was used in immunohistochemistry to determine if ERCC1 and Tau expression correlates with epithelial ovarian cancer outcome
Thu May 01 00:00:00 EDT 2014
Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil.
Cancer research and treatment
Han JJ,Baek SK,Lee JJ,Kim GY,Kim SY,Lee SH
MA5-13912 was used in immunohistochemistry to study the predictive value of measuring TRAP1 and ERCC1 in oxaliplatin plus 5-fluorouracil combination-treated metastatic colorectal cancer
Wed Jan 01 00:00:00 EST 2014
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
American journal of clinical oncology
Cubillo A,Hernando-Requejo O,García-García E,Rodriguez-Pascual J,De Vicente E,Morelli P,Rubio C,López-Ríos F,Muro A,López U,Prados S,Quijano Y,Hidalgo M
MA5-13912 was used in immunohistochemistry to study whether personalized neoadjuvant chemotherapy is feasible in patients with early-stage rectal cancer
Tue Apr 01 00:00:00 EDT 2014
Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.
Anticancer research
Muley TR,Sianidou M,Thomas M,Bischoff H,Dienemann H,Meister M,Schneider MA,Schnabel PA,Warth A
MA5-13912 was used in immunohistochemistry - paraffin section to discuss the use of excision repair cross-complementing rodent repair deficiency, complementation group 1 expression for selecting patients for platinum-based chemotherapy.
Tue Jul 01 00:00:00 EDT 2014
ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples.
Revista portuguesa de pneumologia
Kalogeraki A,Karvela-Kalogeraki I,Tamiolakis D,Petraki P,Saridaki Z,Tzardi M
MA5-13912 was used in immunohistochemistry to study the prognostic value of ECCR1 and EGFR expression measured in non-small cel lung cancer fine-needle aspiration biopsies
Mon Apr 06 00:00:00 EDT 2015
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
The New England journal of medicine
Friboulet L,Olaussen KA,Pignon JP,Shepherd FA,Tsao MS,Graziano S,Kratzke R,Douillard JY,Seymour L,Pirker R,Filipits M,André F,Solary E,Ponsonnailles F,Robin A,Stoclin A,Dorvault N,Commo F,Adam J,Vanhecke E,Saulnier P,Thomale J,Le Chevalier T,Dunant A,Rousseau V,Le Teuff G,Brambilla E,Soria JC
MA5-13912 was used in immunohistochemistry to study whether there is a correlation between DNA repair capacity following cisplatin therapy and the expression of different ECCR1 isoforms
Thu Mar 21 00:00:00 EDT 2013
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research
Mehra R,Zhu F,Yang DH,Cai KQ,Weaver J,Singh MK,Nikonova AS,Golemis EA,Flieder DB,Cooper HS,Lango M,Ridge JA,Burtness B
MA5-13912 was used in immunocytochemistry, immunohistochemistry, and western blot to study the prognostic value of ERRC1 in p16-negative squamous cell head and neck cancers
Sun Dec 01 00:00:00 EST 2013
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
British journal of cancer
Tiseo M,Bordi P,Bortesi B,Boni L,Boni C,Baldini E,Grossi F,Recchia F,Zanelli F,Fontanini G,Naldi N,Campanini N,Azzoni C,Bordi C,Ardizzoni A
MA5-13912 was used in immunohistochemistry to study the potential prognostic and predictive value of ERCC1 and BRCA1 immunohistochemical expression and polymorphisms in advanced non-small cell lung cancer
Tue Apr 30 00:00:00 EDT 2013
Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.
British journal of cancer
Mendoza J,Martínez J,Hernández C,Pérez-Montiel D,Castro C,Fabián-Morales E,Santibáñez M,González-Barrios R,Díaz-Chávez J,Andonegui MA,Reynoso N,Oñate LF,Jiménez MA,Núñez M,Dyer R,Herrera LA
MA5-13912 was used in immunohistochemistry to study the relationship between the response of testicular germ cell tumors to cisplatin therapy and ERCC1 and XPA polymorphisms and expression levels
Tue Jul 09 00:00:00 EDT 2013
Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Lung cancer (Amsterdam, Netherlands)
Vassalou H,Stathopoulos E,Fiolitaki G,Koutsopoulos A,Voutsina A,Georgoulias V,Mavroudis D
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy
Fri Nov 01 00:00:00 EDT 2013
Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.
Clinical lung cancer
Kao SC,Lee K,Klebe S,Henderson D,McCaughan B,Vardy J,Clarke S,van Zandwijk N
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 and thymidylate synthase expression in malignant pleural mesothelioma
Fri Mar 01 00:00:00 EST 2013
Clinicopathological significance of ERCC1 expression in breast cancer.
Pathology, research and practice
Gerhard R,Carvalho A,Carneiro V,Bento RS,Uemura G,Gomes M,Albergaria A,Schmitt F
MA5-13912 was used in immunohistochemistry to study the predictive and prognostic value of ERCC1 expression in breast cancer
Sat Jun 01 00:00:00 EDT 2013
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Journal of cardiothoracic surgery
Yan D,Wei P,An G,Chen W
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression and clinicopathologigal parameters in Chinese patients with stage III/N2 non-small cell lung cancer
Mon Jun 10 00:00:00 EDT 2013
Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.
PloS one
Yamashita F,Azuma K,Yoshida T,Yamada K,Kawahara A,Hattori S,Takeoka H,Zaizen Y,Kawayama T,Kage M,Hoshino T
MA5-13912 was used in immunohistochemistry to study the prognostic value of EGFR mutations and ERCC1 expression in patients receiving platinum-based chemotherapy for non-small cell lung cancer
Mon Apr 14 00:00:00 EDT 2014
Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Zimling ZG,Sørensen JB,Gerds TA,Bech C,Andersen CB,Santoni-Rugiu E
MA5-13912 was used in immunohistochemistry to study the prognostic value of low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine
Sun Jan 01 00:00:00 EST 2012
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).
Clinical cancer research : an official journal of the American Association for Cancer Research
Thariat J,Bensadoun RJ,Etienne-Grimaldi MC,Grall D,Penault-Llorca F,Dassonville O,Bertucci F,Cayre A,De Raucourt D,Geoffrois L,Finetti P,Giraud P,Racadot S,Morinière S,Sudaka A,Van Obberghen-Schilling E,Milano G
MA5-13912 was used in immunohistochemistry to study the outcomes of gefitinib treatment in head and neck cancer patients
Sat Sep 15 00:00:00 EDT 2012
p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients.
Cancer
Planchard D,Camara-Clayette V,Dorvault N,Soria JC,Fouret P
MA5-13912 was used in immunohistochemistry to study the role of p38-MAPK in lung cancer cell viability in light and non-smoking patients
Mon Oct 15 00:00:00 EDT 2012
Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Oral oncology
Huang PY,Li Y,Mai HQ,Luo RZ,Cai YC,Zhang L
MA5-13912 was used in immunohistochemistry to study the predictive value of ERCC1 expression in locoregionally advanced nasopharyngeal carcinoma patients treated with cisplatin-based chemotherapy
Mon Oct 01 00:00:00 EDT 2012
Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy.
Clinical lung cancer
Monica V,Longo M,Felice B,Scagliotti GV,Papotti M,Novello S
MA5-13912 was used in immunohistochemistry to study whether hormone receptor expression is correlated with clinical outcome in advanaced lung cancer treated with chemotherapy
Thu Nov 01 00:00:00 EDT 2012
Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status.
Head & neck
Hao D,Lau HY,Eliasziw M,Box A,Diaz R,Klimowicz AC,Shin B,Lees-Miller SP,Magliocco AM
MA5-13912 was used in immunohistochemistry to characterize ERCC1 protein in squamous cell carcinomas of the head and neck and the effects of treatment
Fri Jun 01 00:00:00 EDT 2012
Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer.
Genome integrity
Facista A,Nguyen H,Lewis C,Prasad AR,Ramsey L,Zaitlin B,Nfonsam V,Krouse RS,Bernstein H,Payne CM,Stern S,Oatman N,Banerjee B,Bernstein C
MA5-13912 was used in immunohistochemistry to study the role of deficient expression of DNA repair enzymes in early progression to sporadic colon cancer
Wed Apr 11 00:00:00 EDT 2012
SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype.
Nature genetics
Stoepker C,Hain K,Schuster B,Hilhorst-Hofstee Y,Rooimans MA,Steltenpool J,Oostra AB,Eirich K,Korthof ET,Nieuwint AW,Jaspers NG,Bettecken T,Joenje H,Schindler D,Rouse J,de Winter JP
MA5-13912 was used in immunoprecipitation and western blot to study a novel Fanconi anemia subtype in which SLX4 is mutated
Tue Feb 01 00:00:00 EST 2011
Mutations of the SLX4 gene in Fanconi anemia.
Nature genetics
Kim Y,Lach FP,Desetty R,Hanenberg H,Auerbach AD,Smogorzewska A
MA5-13912 was used in immunoprecipitation to study SLX4 mutations in two patients with Fanconi anemia
Tue Feb 01 00:00:00 EST 2011
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Gadgeel SM,Ruckdeschel JC,Patel BB,Wozniak A,Konski A,Valdivieso M,Hackstock D,Chen W,Belzer K,Burger AM,Marquette L,Turrisi A
MA5-13912 was used in immunohistochemistry to study the efficacy and feasibility of integrating pemetrexed in the therapy of patients with stage III non-small cell lung cancer
Sun May 01 00:00:00 EDT 2011
Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
European journal of cancer (Oxford, England : 1990)
Rodrigo RS,Nathalie A,Elodie T,Gonzalo GA,Philippe T,Françoise D,Julien D,Angela C,Bérénice B,Jean-Yves B,Jean-Michel C,Jean B,Sylvie B,Axel le C
MA5-13912 was used in immunohistochemistry to study the predictive value of Topo2A protein expression in survival of locally advanced soft tissues sarcomas
Wed Jun 01 00:00:00 EDT 2011
The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Hasegawa K,Kato R,Torii Y,Ichikawa R,Oe S,Udagawa Y
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression levels in patients with uterine cervical adenocarcinoma
Tue Nov 01 00:00:00 EDT 2011
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Annals of surgical oncology
Maithel SK,Coban I,Kneuertz PJ,Kooby DA,El-Rayes BF,Kauh JS,Sarmiento J,Staley CA,Volkan Adsay N
MA5-13912 was used in immunohistochemistry to study the predictive value of ERCC1 expression in pancreatic adenocarcinoma
Thu Sep 01 00:00:00 EDT 2011
Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Digestive diseases and sciences
Jeong SH,Han JH,Kim JH,Ahn MS,Hwang YH,Lee HW,Kang SY,Park JS,Choi JH,Lee KJ,Sheen SS,Lim HY
MA5-13912 was used in immunohistochemistry to study the prognostic significance of Bax, ERCC1, and TS in advanced gastric cancer patients treated with FOLFOX palliative chemotherapy
Sat Jan 01 00:00:00 EST 2011
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
Kim KH,Kwon HC,Oh SY,Kim SH,Lee S,Kwon KA,Jang JS,Kim MC,Kim SJ,Kim HJ
MA5-13912 was used in immunohistochemistry to investigate the prognostic significance of multiple genes for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
Tue Feb 01 00:00:00 EST 2011
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology
Vilmar AC,Santoni-Rugiu E,Sørensen JB
MA5-13912 was used in immunohistochemistry to evaluate excision repair cross-complementation group 1 ERCC1 as a biomarker for treatment of advanced non-small-cell lung cancer
Wed Sep 01 00:00:00 EDT 2010
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Righi L,Papotti MG,Ceppi P,Billè A,Bacillo E,Molinaro L,Ruffini E,Scagliotti GV,Selvaggi G
MA5-13912 was used in immunohistochemistry to investigate the prognostic effectiveness of thymidylate synthase in the chemotherapy of malignant pleural mesothelioma
Sat Mar 20 00:00:00 EDT 2010
ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Skov BG,Holm B,Erreboe A,Skov T,Mellemgaard A
MA5-13912 was used in immunohistochemistry to study the roles of ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung
Thu Apr 01 00:00:00 EDT 2010
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.
European journal of cancer (Oxford, England : 1990)
Vilmar A,Santoni-Rugiu E,Sørensen JB
MA5-13912 was used in immunohistochemistry to detect advanced lung cancer using the ERCC1 biomarker
Tue Jun 01 00:00:00 EDT 2010
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
British journal of cancer
Lee S,Park YH,Kim KH,Cho EY,Ahn YC,Kim K,Shim YM,Ahn JS,Park K,Im YH
MA5-13912 was used in immunohistochemistry to study biomarkers for predicting the response to capecitabine and cisplatin combination chemotherapy in metastatic oesophageal squamous cell cancer
Tue Sep 07 00:00:00 EDT 2010
Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Doll CM,Prystajecky M,Eliasziw M,Klimowicz AC,Petrillo SK,Craighead PS,Hao D,Diaz R,Lees-Miller SP,Magliocco AM
MA5-13912 was used in immunohistochemistry to study the association of low ERCC1 expression with poor survival in cervical cancer patients treated with radiation therapy
Mon Nov 01 00:00:00 EDT 2010
Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
Lung cancer (Amsterdam, Netherlands)
Jeong SH,Jung JH,Han JH,Kim JH,Choi YW,Lee HW,Kang SY,Hwang YH,Ahn MS,Choi JH,Oh YT,Chun M,Kang S,Park KJ,Hwang SC,Sheen SS
MA5-13912 was used in immunohistochemistry to study the predictive value of Bcl-2 expression in locally advanced non-small cell lung cancer undergoing cisplatin therapy
Sat May 01 00:00:00 EDT 2010
Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Endocrine-related cancer
Malandrino P,Al Ghuzlan A,Castaing M,Young J,Caillou B,Travagli JP,Elias D,de Baere T,Dromain C,Paci A,Chanson P,Schlumberger M,Leboulleux S,Baudin E
MA5-13912 was used in immunohistochemistry to investigate the effect of specific markers for adrenocortical carcinoma prognosis after specific chemotherapy
Wed Sep 01 00:00:00 EDT 2010
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
Gynecologic oncology
Scheil-Bertram S,Tylus-Schaaf P,du Bois A,Harter P,Oppitz M,Ewald-Riegler N,Fisseler-Eckhoff A
MA5-13912 was used in immunohistochemistry to investigate the relationship of ERCC1 expression with survival of ovarian cancer patients
Mon Nov 01 00:00:00 EDT 2010
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
Medical oncology (Northwood, London, England)
Wang X,Zhao J,Yang L,Mao L,An T,Bai H,Wang S,Liu X,Feng G,Wang J
MA5-13912 was used in immunohistochemistry to study ERCC1 expression and tumor response to platinum-based chemotherapy in Chinese non-small cell lung cancer patients
Tue Jun 01 00:00:00 EDT 2010
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
Cancer chemotherapy and pharmacology
Bamias A,Karina M,Papakostas P,Kostopoulos I,Bobos M,Vourli G,Samantas E,Christodoulou Ch,Pentheroudakis G,Pectasides D,Dimopoulos MA,Fountzilas G
MA5-13912 was used in immunohistochemistry to study adjuvant platinum/docetaxel chemotherapy with or without radiation in a phase III gastric cancer clinical trial
Sat May 01 00:00:00 EDT 2010
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
Japanese journal of clinical oncology
Shao YY,Kuo KT,Hu FC,Lu YS,Huang CS,Liau JY,Lee WC,Hsu C,Kuo WH,Chang KJ,Lin CH,Cheng AL
MA5-13912 was used in immunohistochemistry to study the predictive and prognostic value of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
Thu Apr 01 00:00:00 EDT 2010
Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.
Anticancer research
Mancuso A,Sacchetta S,Saletti PC,Tronconi C,Milesi L,Garassino M,Martelli O,Leone A,Zivi A,Cerbone L,Recine F,Sollami R,Labianca R,Cavalli F,Sternberg CN
MA5-13912 was used in immunohistochemistry to study the molecular and clinical determinants of survival in pancreatic cancer patients treated with second-line chemotherapy
Fri Oct 01 00:00:00 EDT 2010
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology
Planchard D,Domont J,Taranchon E,Monnet I,Tredaniel J,Caliandro R,Validire P,Besse B,Soria JC,Fouret P
MA5-13912 was used in immunohistochemistry to investigate ERCC1, RPA and XPF expression in different types of smokers with lung adenocarcinoma
Wed Jul 01 00:00:00 EDT 2009
Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Holm B,Mellemgaard A,Skov T,Skov BG
MA5-13912 was used in immunohistochemistry to study the association between ERCC1 status and overall survival after chemotherapy for inoperable non-small cell lung cancer
Thu Sep 10 00:00:00 EDT 2009
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Gomez-Roca C,Raynaud CM,Penault-Llorca F,Mercier O,Commo F,Morat L,Sabatier L,Dartevelle P,Taranchon E,Besse B,Validire P,Italiano A,Soria JC
MA5-13912 was used in immunohistochemistry to study the differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
Thu Oct 01 00:00:00 EDT 2009
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.
British journal of cancer
Han SW,Oh DY,Im SA,Park SR,Lee KW,Song HS,Lee NS,Lee KH,Choi IS,Lee MH,Kim MA,Kim WH,Bang YJ,Kim TY
MA5-13912 was used in immunohistochemistry to study the efficacy of combined cetuximab and modified FOLFOX6 treatment in a phase II gastric cancer trial
Tue Jan 27 00:00:00 EST 2009
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Lung cancer (Amsterdam, Netherlands)
Lee HW,Choi YW,Han JH,Kim JH,Jung JH,Jeong SH,Kang SY,Choi JH,Oh YT,Park KJ,Hwang SC,Sheen SS
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 protein expression in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
Tue Sep 01 00:00:00 EDT 2009
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands)
Kim YH,Ishii G,Goto K,Ota S,Kubota K,Murata Y,Mishima M,Saijo N,Nishiwaki Y,Ochiai A
MA5-13912 was used in immunohistochemistry to investigate the clinical significance of breast cancer resistance protein in small-cell lung cancer
Wed Jul 01 00:00:00 EDT 2009
Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Endocrine-related cancer
Ronchi CL,Sbiera S,Kraus L,Wortmann S,Johanssen S,Adam P,Willenberg HS,Hahner S,Allolio B,Fassnacht M
MA5-13912 was used in immunohistochemistry to investigate the prognostic significance of excision repair cross complementing group 1 in adrenocortical carcinoma patients
Tue Sep 01 00:00:00 EDT 2009
The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Steffensen KD,Waldstrøm M,Jakobsen A
MA5-13912 was used in immunohistochemistry to study ERCC1 protein expression as a predictor of platinum resistance in epithelial ovarian cancer
Wed Jul 01 00:00:00 EDT 2009
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.
Journal of oncology
Fountzilas G,Kalogera-Fountzila A,Lambaki S,Wirtz RM,Nikolaou A,Karayannopoulou G,Bobos M,Kotoula V,Murray S,Lambropoulos A,Aravantinos G,Markou K,Athanassiou E,Misailidou D,Kalogeras KT,Skarlos D
MA5-13912 was used in immunohistochemistry to study the predictive value of several biomarkers in patients undergoing treatment for locally advanced head and neck cancerr
Thu Jul 14 00:00:00 EDT 2011
The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells.
Nucleic acids research
Al-Minawi AZ,Saleh-Gohari N,Helleday T
MA5-13912 was used in western blot to investigate the role of ERCC1/XPF endonuclease in DNA repair in Chinese hamster cell line UV4
Tue Jan 01 00:00:00 EST 2008
Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research
Kim MK,Cho KJ,Kwon GY,Park SI,Kim YH,Kim JH,Song HY,Shin JH,Jung HY,Lee GH,Choi KD,Kim SB
MA5-13912 was used in immunohistochemistry to study ERCC1 as a predictive marker of the benefit of preoperative chemoradiotherapy in locally advanced esophageal cancers
Tue Jul 01 00:00:00 EDT 2008
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.
European journal of cancer (Oxford, England : 1990)
Kim MK,Cho KJ,Kwon GY,Park SI,Kim YH,Kim JH,Song HY,Shin JH,Jung HY,Lee GH,Choi KD,Kim SB
MA5-13912 was used in immunohistochemistry to study the value of ERCC1 expression in predicting chemoradiation resistance and poor outcome in oesophageal cancer
Tue Jan 01 00:00:00 EST 2008
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
Lung cancer (Amsterdam, Netherlands)
Lee HW,Han JH,Kim JH,Lee MH,Jeong SH,Kang SY,Choi JH,Oh YT,Park KJ,Hwang SC,Sheen SS,Lim HY
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression in small cell lung cancer
Tue Jan 01 00:00:00 EST 2008
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands)
Fujii T,Toyooka S,Ichimura K,Fujiwara Y,Hotta K,Soh J,Suehisa H,Kobayashi N,Aoe M,Yoshino T,Kiura K,Date H
MA5-13912 was used in immunohistochemistry to study ERCC1 expression and the response to cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer
Sat Mar 01 00:00:00 EST 2008
Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms.
Mechanisms of ageing and development
Wu Y,Mitchell TR,Zhu XD
MA5-13912 was used in immunoprecipitation to study the distinct mechanisms by which XPF-ERCC1 regulates TRF2 function and maintenance of telomere length
Wed Oct 01 00:00:00 EDT 2008
ERCC1 expression in triple negative breast carcinoma: the paradox revisited.
Breast cancer research and treatment
Sidoni A,Cartaginese F,Colozza M,Gori S,Crinó L
MA5-13912 was used in immunohistochemistry to study ERCC1 expression in triple negative breast carcinoma
Wed Oct 01 00:00:00 EDT 2008
Molecular characterization of spontaneous mesenchymal stem cell transformation.
PloS one
Rubio D,Garcia S,Paz MF,De la Cueva T,Lopez-Fernandez LA,Lloyd AC,Garcia-Castro J,Bernad A
MA5-13912 was used in western blot to investigate the molecular mechanisms of spontaneous mesenchymal stem cell transformation
Wed Jan 02 00:00:00 EST 2008
Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology
Taillade L,Penault-Llorca F,Boulet T,Fouret P,Michiels S,Taranchon E,Mountzios G,Validire P,Domont J,Girard P,Grunenwald D,Le Chevalier T,Soria JC
MA5-13912 was used in immunohistochemistry to compare the expression of diagnostic biomarkers in bronchial biopsies and surgical specimens of non-small-cell lung cancer
Fri Jun 01 00:00:00 EDT 2007
Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
Handra-Luca A,Hernandez J,Mountzios G,Taranchon E,Lacau-St-Guily J,Soria JC,Fouret P
MA5-13912 was used in immunohistochemistry to study the value of ERCC1 expression in predicting response and survival in head and neck squamous cell carcinoma treated with cisplatin
Sun Jul 01 00:00:00 EDT 2007
Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Cancer science
Azuma K,Komohara Y,Sasada T,Terazaki Y,Ikeda J,Hoshino T,Itoh K,Yamada A,Aizawa H
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 in non-small cell lung cancer patients treated with platinum-based chemotherapy
Sat Sep 01 00:00:00 EDT 2007
XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening.
DNA repair
Wu Y,Zacal NJ,Rainbow AJ,Zhu XD
MA5-13912 was used in western blot to study the effect of conserved nuclease domain mutations of XPF on DNA reair and TRF2-mediated shortening of telomeres
Sun Feb 04 00:00:00 EST 2007
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
The New England journal of medicine
Olaussen KA,Dunant A,Fouret P,Brambilla E,André F,Haddad V,Taranchon E,Filipits M,Pirker R,Popper HH,Stahel R,Sabatier L,Pignon JP,Tursz T,Le Chevalier T,Soria JC
MA5-13912 was used in immunohistochemistry to study the role of ERCC1 in repairing DNA in non-small-cell lung cancer treated with cisplatin
Thu Sep 07 00:00:00 EDT 2006
ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
Lung cancer (Amsterdam, Netherlands)
Wachters FM,Wong LS,Timens W,Kampinga HH,Groen HJ
MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1, hRad51, and BRCA1 protein expression in patients with stage III/IV non-small cell lung cancer
Tue Nov 01 00:00:00 EST 2005